Ruxolitinib belongs to the JAK inhibitor class, and important safety considerations apply to both topical and oral formulations.
Rutinib Cream Safety
The current OPZELURA label carries a boxed warning concerning serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis associated with JAK inhibitors.
The label also identifies:
- serious infections
- tuberculosis
- malignancies
- thrombosis
- cytopenias
- non-melanoma skin cancer
Patients should be monitored appropriately.
Rutinib 5 mg Safety
Oral ruxolitinib requires monitoring of blood counts and consideration of infections, cytopenias, malignancy and other systemic risks.
Current JAKAFI labeling specifically addresses infections, thrombocytopenia, anemia and neutropenia among important safety considerations.
Ruxotor 10 mg Safety
Ruxotor 10 mg is an oral formulation and should be evaluated using the safety information applicable to oral ruxolitinib and the specific product authorization.
Important Safety Areas
Depending on formulation and patient circumstances, clinicians may consider:
- serious infections
- tuberculosis
- opportunistic infections
- malignancy
- cardiovascular events
- thrombosis
- cytopenias
- lipid abnormalities
- liver abnormalities
- renal function
- vaccination
- pregnancy
- lactation
- drug interactions
Not every risk applies with the same frequency or clinical significance to every formulation.